ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $23.00 target price on the stock.

Several other analysts have also issued reports on IBRX. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. BTIG Research began coverage on shares of ImmunityBio in a research report on Thursday, March 12th. They set a “buy” rating and a $13.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, April 14th. HC Wainwright upped their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Trading Down 1.2%

NASDAQ IBRX opened at $8.10 on Tuesday. The firm’s fifty day moving average price is $8.06 and its two-hundred day moving average price is $4.82. ImmunityBio has a 1 year low of $1.83 and a 1 year high of $12.43. The firm has a market capitalization of $8.33 billion, a P/E ratio of -21.32 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. On average, research analysts anticipate that ImmunityBio will post -0.31 EPS for the current fiscal year.

Insider Transactions at ImmunityBio

In other news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director owned 2,850,821 shares of the company’s stock, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 275,000 shares of company stock valued at $2,934,500. 69.48% of the stock is currently owned by corporate insiders.

Institutional Trading of ImmunityBio

A number of hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ increased its position in ImmunityBio by 347.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,028,921 shares during the period. Heights Capital Management Inc. bought a new position in ImmunityBio during the third quarter worth about $16,152,000. Vanguard Group Inc. increased its position in ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after acquiring an additional 5,837,898 shares during the period. MOR Wealth Management LLC bought a new position in ImmunityBio during the fourth quarter worth about $494,000. Finally, Rafferty Asset Management LLC increased its position in ImmunityBio by 79.2% during the third quarter. Rafferty Asset Management LLC now owns 452,458 shares of the company’s stock worth $1,113,000 after acquiring an additional 199,990 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial expansion — ImmunityBio announced ANKTIVA is now commercially available in Saudi Arabia for bladder and lung cancer, representing early international market traction and potential revenue upside in the MENA region. ImmunityBio Announces ANKTIVA Is Now Available in Saudi Arabia
• Positive Sentiment: Analyst bullishness — D. Boral Capital reaffirmed a “buy” rating with a $23 price target, implying substantial upside vs. the current share level and lending support to a growth/recovery narrative. Benzinga Coverage: DBoral Rating
• Positive Sentiment: Strong YTD momentum / commercial catalysts — Media noted IBRX has rallied sharply year-to-date and management/founder comments highlighting additional clinical signals (e.g., potential in breast cancer) that keep bullish narratives alive. MSN: IBRX stock has quadrupled this year
• Neutral Sentiment: Market caution suggested by commentators — Jim Cramer and other commentators urged waiting for clearer data or regulatory clarity before taking a large position, which can temper speculative inflows despite bullish headlines. InsiderMonkey: Jim Cramer Suggests Waiting
• Negative Sentiment: Large wave of class‑action filings and firm reminders — Multiple law firms have filed or announced investigations and are soliciting lead‑plaintiff candidates for a securities class action covering purchases between Jan. 19 and Mar. 24, 2026; the May 26 lead‑plaintiff deadline is driving a flurry of notices. This increases legal overhang and potential future liabilities. Pomerantz Investor Alert
• Negative Sentiment: Investigations reference FDA warning/alleged misleading efficacy claims — Litigation notices and at least one investor alert cite an FDA warning letter about claims made by the company’s chairman regarding ANKTIVA efficacy; that regulatory angle materially raises risk and likely explains negative investor reaction despite commercial news. Hagens Berman: Investor Deadline & FDA warning mention

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.